Loading...

SOHO 2026 Annual Meeting

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Home Posters by Code Posters by Title Authors Affiliations Topics Sessions Videos Audios Previous meetings

Topics

Select Topic

Showing 230 results for "Acute Myeloid Leukemia (AML)".

Thumbnail for Phenotype-Specific Safety Differences Between Gilteritinib and Midostaurin in AML: A FAERS Analysis Highlighting Differentiation Syndrome Signal

AML - 103

Phenotype-Specific Safety Differences Between Gilteritinib and Midostaurin in AML: A FAERS Analysis Highlighting Differentiation Syndrome Signal

Edward Mwarangu

Poster Presenter: Edward Mwarangu

Thumbnail for Comparative Inpatient Mortality and Hospitalization Burden in AML, ALL, and DLBCL: A Nationwide Analysis, 2016-2020

AML - 1032

Comparative Inpatient Mortality and Hospitalization Burden in AML, ALL, and DLBCL: A Nationwide Analysis, 2016-2020

Srijani Thannir

Poster Presenter: Srijani Thannir

Thumbnail for Plasma Cytokeratin-18 Fragment in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia

Previous 1 2 3 4 5 6...26 Next

Copyright © 2015-2026, ePostersLive® SciGen is a registered trademark of SciGen Technologies S.A. Patent pending.

AML - 107

Plasma Cytokeratin-18 Fragment in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia

Mostafa El Razzaz

Poster Presenter: Mostafa El Razzaz

Thumbnail for Pretransplant Measurable Residual Disease and Survival After Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia: Does Donor Type Change the Risk?

AML - 1079

Pretransplant Measurable Residual Disease and Survival After Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia: Does Donor Type Change the Risk?

Aakriti Adhikari

Poster Presenter: Aakriti Adhikari

Thumbnail for Fludarabine/Melphalan Versus Fludarabine/Busulfan Conditioning in AML Undergoing Allogeneic HCT

AML - 1080

Fludarabine/Melphalan Versus Fludarabine/Busulfan Conditioning in AML Undergoing Allogeneic HCT

Aakriti Adhikari

Poster Presenter: Aakriti Adhikari

Thumbnail for Validation of an FLT3 Activity Signature to Predict FLT3 Inhibitor Response in Acute Myeloid Leukemia

AML - 1085

Validation of an FLT3 Activity Signature to Predict FLT3 Inhibitor Response in Acute Myeloid Leukemia

Andrea Palasciano

Poster Presenter: Andrea Palasciano

Thumbnail for CRHBP Activates NF-?B Signaling Through TNIP1 Inhibition in Leukemic Stem Cells: A Novel CRH-Independent Mechanism of Treatment Resistance

AML - 109

CRHBP Activates NF-?B Signaling Through TNIP1 Inhibition in Leukemic Stem Cells: A Novel CRH-Independent Mechanism of Treatment Resistance

Ryutaro Taenaka

Poster Presenter: Ryutaro Taenaka

Thumbnail for Early Transfusion Independence as a Real-World Prognostic Marker After Hypomethylating Agent-Venetoclax Therapy in Older Adults With Acute Myeloid Leukemia

AML - 1096

Early Transfusion Independence as a Real-World Prognostic Marker After Hypomethylating Agent-Venetoclax Therapy in Older Adults With Acute Myeloid Leukemia

Fathima Shehnaz Ayoobkhan

Poster Presenter: Fathima Shehnaz Ayoobkhan

Thumbnail for Myeloablative vs Reduced-Intensity Conditioning with Post-Transplant Cyclophosphamide in Haploidentical Hematopoietic Cell Transplantation for AML and MDS: A CIBMTR Registry Analysis

AML - 1104

Myeloablative vs Reduced-Intensity Conditioning with Post-Transplant Cyclophosphamide in Haploidentical Hematopoietic Cell Transplantation for AML and MDS: A CIBMTR Registry Analysis

Mohammad Ebad Ur Rehman

Poster Presenter: Mohammad Ebad Ur Rehman

ePosters in

Topics Sessions

Acute Lymphoblastic Leukemia (ALL)(71)Acute Myeloid Leukemia (AML)(230)Aggressive B-Cell Lymphoma (ABCL)(114)Cellular Therapy (CT)(128)Chronic Lymphocytic Leukemia (CLL)(110)Chronic Myeloid Leukemia (CML)(55)Hodgkin Lymphoma (HL)(54)Indolent B-Cell Lymphoma (IBCL)(47)Mantle Cell Lymphoma (MCL)(23)Multiple Myeloma (MM)(234)

Previous 1 2 Next

Sponsors